Safety and tolerability of edivoxetine as adjunctive treatment to selective serotonin reuptake inhibitor antidepressants for patients with major depressive disorder

Safety and tolerability of edivoxetine as adjunctive treatment to selective serotonin reuptake inhibitor antidepressants for patients with major depressive disorder

Objective: The aim of this analysis was to assess the safety profile of edivoxetine as adjunctive treatment to selective serotonin reuptake inhibitor (SSRI) antidepressants. Methods: A pooled analysis was conducted on data obtained from the integrated safety database of edivoxetine as adjunctive...

Full description

Bibliographic Details
Main Authors:	James M Martinez, Margaret B Ferguson, Beth A Pangallo, Tina M Oakes, JonDavid Sparks, Mary Anne Dellva, Qi Zhang, Peng Liu, Mark Bangs, Jonna Ahl, Celine Goldberger
Format:	Article
Language:	English
Published:	BioExcel Publishing Ltd 2015-05-01
Series:	Drugs in Context
Subjects:	norepinephrine reuptake inhibitor serotonin reuptake inhibitor second-generation antidepressive agent major depressive disorder adjunctive therapy drug safety drug tolerability
Online Access:	http://www.drugsincontext.com/safety-tolerability-edivoxetine-adjunctive-treatment-selective-serotonin-reuptake-inhibitor-antidepressants-patients-major-depressive-disorder/

Similar Items

Design and Synthesis of Arylamidine Derivatives as Serotonin/Norepinephrine Dual Reuptake Inhibitors
by: Hui Wen, et al.
Published: (2019-01-01)

Antidepressant Drugs Effects on Blood Pressure
by: Anna Calvi, et al.
Published: (2021-08-01)

Chirality of Modern Antidepressants: An Overview
by: Monica Budău, et al.
Published: (2017-12-01)

Analytical methods for determination of selective serotonin reuptake inhibitor antidepressants
by: Şentürk Zühre, et al.
Published: (2011-06-01)

Selective serotonin reuptake inhibitors may lead to improved cataract surgery outcomes in patients with amblyopia
by: Xin KZ, et al.
Published: (2019-08-01)

Which adverse effects influence the dropout rate in selective serotonin reuptake inhibitor (SSRI) treatment? Results for 50,824 patients
by: Kostev, Karel, et al.
Published: (2014-10-01)

The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone
by: McIntyre RS
Published: (2017-11-01)

Selective serotonin reuptake inhibitors and cardiovascular events: A systematic review
by: Mohammad Hassan Nezafati, et al.
Published: (2016-01-01)

Selective serotonin reuptake inhibitor (SSRI) antidepressants, prolactin and breast cancer
by: Janet eAshbury, et al.
Published: (2012-12-01)

Serotonin and norepinephrine reuptake inhibitor antidepressants: a look through the prism of their 30-year history
by: D. S. Danilov
Published: (2018-12-01)

Monoaminergic Antidepressants in the Relief of Pain: Potential Therapeutic Utility of Triple Reuptake Inhibitors (TRIs)
by: Bruno P. Guiard, et al.
Published: (2011-01-01)

Pharmacological Characterization of Toludesvenlafaxine as a Triple Reuptake Inhibitor
by: Haibo Zhu, et al.
Published: (2021-09-01)

Selective serotonin reuptake inhibitors (SSRIs) and breast cancer : a record linkage study
by: Ashbury, Janet E.
Published: (2008)

Is the Antidepressant Activity of Selective Serotonin Reuptake Inhibitors Mediated by Nicotinic Acetylcholine Receptors?
by: Hugo R. Arias, et al.
Published: (2021-04-01)

Bradycardia Caused by interaction of Venlafaxine and Cyclosporine: A case report
by: Marzieh Azizi, et al.
Published: (2019-09-01)

Selective serotonin reuptake inhibitors and risk for gastrointestinal bleeding
by: Batić-Mujanović Olivera, et al.
Published: (2014-01-01)

Antidepressants and cardiovascular adverse events: A narrative review
by: Mohammad Hassan Nezafati, et al.
Published: (2015-09-01)

Apathy syndrome in a patient previously treated with selective serotonin reuptake inhibitors for depression
by: Hye-Geum Kim, et al.
Published: (2019-09-01)

A meta-analysis of effects of selective serotonin reuptake inhibitors on blood pressure in depression treatment: outcomes from placebo and serotonin and noradrenaline reuptake inhibitor controlled trials
by: Zhong Z, et al.
Published: (2017-11-01)

Review of sexual dysfunction due to selective serotonin reuptake inhibitors
by: P Srilakshmi, et al.
Published: (2012-01-01)

Acute Angle-Closure—A Rare but Vision-Threatening Ocular Adverse Effect of Selective Serotonin Reuptake Inhibitors
by: Michał Wiciński, et al.
Published: (2021-04-01)

The Risk of Congenital Heart Anomalies Following Prenatal Exposure to Serotonin Reuptake Inhibitors—Is Pharmacogenetics the Key?
by: Aizati N. A. Daud, et al.
Published: (2016-08-01)

The noradrenergic paradox: implications in the management of depression and anxiety
by: Montoya A, et al.
Published: (2016-03-01)

Reboxetine in the light of science and clinical practice
by: Anna Wasik, et al.
Published: (2019-02-01)

A case of severe paraneoplastic itch resistant to antihistamines and responding to serotonin reuptake inhibitors
by: Ines Werda, et al.
Published: (2021-07-01)

Selective serotonin reuptake inhibitors-paroxetine induced galactorrhea in a case of somatoform disorder
by: Ajay Halder, et al.
Published: (2015-01-01)

Maternal Serotonin Reuptake Inhibitor Antidepressants Have Acute Effects on Fetal Heart Rate Variability in Late Gestation
by: Kayleigh S. J. Campbell, et al.
Published: (2021-08-01)

Study of antinociceptive activity of SSRI (fluoxetine and escitalopram) and atypical antidepressants (venlafaxine and mirtazepine) and their interaction with morphine and naloxone in mice
by: Pranav Sikka, et al.
Published: (2011-01-01)

Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review
by: Amber N. Edinoff, et al.
Published: (2021-08-01)

Decreased Growth with Serotonin Reuptake Inhibitors
by: J Gordon Millichap
Published: (2002-08-01)

Mild serotonin syndrome: A report of 12 cases
by: Sanjay Prakash, et al.
Published: (2015-01-01)

The Association between Selective Serotonin Reuptake Inhibitors (SSRIs) Use and the Risk of Bladder Cancer: A Nationwide Population-Based Cohort Study
by: Yi-Chun Liu, et al.
Published: (2020-05-01)

Are Noradrenergic Transmission Reducing Drugs Antidepressants?
by: Paul J. Fitzgerald
Published: (2021-09-01)

Selective serotonin reuptake inhibitors and Alzheimer’s disease
by: Bernadette Mdawar, et al.
Published: (2020-01-01)

Association of the Polygenic Scores for Personality Traits and Response to Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder
by: Azmeraw T. Amare, et al.
Published: (2018-03-01)

Antidepressant-like drug effects in juvenile and adolescent mice in the tail suspension test: Relationship with hippocampal serotonin and norepinephrine transporter expression and function.
by: Nathan C Mitchell, et al.
Published: (2013-10-01)

Pediatric Therapeutic Drug Monitoring for Selective Serotonin Reuptake Inhibitors
by: Jeffrey R. Strawn, et al.
Published: (2021-10-01)

Commentary: Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression.
by: Eiko I Fried, et al.
Published: (2015-08-01)

Efficacy and safety of duloxetine versus placebo in adolescents with juvenile fibromyalgia: results from a randomized controlled trial
by: Himanshu P. Upadhyaya, et al.
Published: (2019-05-01)

A study to understand the pattern of hyponatremia in patients using selective serotonin reuptake inhibitors and serotonin dopamine antagonists
by: Love Kumar Tomar, et al.
Published: (2021-01-01)